fluorobenzenes has been researched along with Disease Models, Animal in 117 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (4.27) | 18.2507 |
| 2000's | 45 (38.46) | 29.6817 |
| 2010's | 63 (53.85) | 24.3611 |
| 2020's | 4 (3.42) | 2.80 |
| Authors | Studies |
|---|---|
| Bachand, K; Boudreau, D; De Koninck, Y; Doyon, N; Ferrini, F; Gagnon, M; Girard, AA; Godin, AG; Kianicka, I; Labrecque, S; Lorenzo, LE; Plasencia-Fernandez, I; Ribeiro-da-Silva, A | 1 |
| Czarnecka, K; Girek, M; Kłosiński, K; Pasieka, Z; Skibiński, R; Szymański, P | 1 |
| Aoki, Y; Hattori, M; Horikawa, H; Ito, H; Takemura, Y; Yamazaki, M | 1 |
| Andreasen, JT; Kristensen, JL; Odland, AU | 1 |
| Alchahin, AM; Commons, KG; Ehlinger, DG; Guo, Y; Panzini, CM | 1 |
| Liang, X; Su, R; Yu, G | 1 |
| Chen, L; Chen, Z; Fan, L; Fang, J; Ke, D | 1 |
| Bentzer, P; Jungner, M; Lundblad, C | 1 |
| Balligand, JL; Beauloye, C; Hamelet, J; Herijgers, P; Hermida, N; Hilfiker-Kleiner, D; Horman, S; Markl, A; Noppe, G; Van Assche, T; van Bilsen, M; Vanderper, A | 1 |
| Calise, D; Cognet, T; Guilbeau-Frugier, C; Lairez, O; Mialet-Perez, J; Parini, A; Schaak, S | 1 |
| Hasegawa, Y; Kataoka, K; Katayama, T; Kim-Mitsuyama, S; Koibuchi, N; Kuratsu, J; Ma, M; Nakagawa, T; Sueta, D; Toyama, K; Uekawa, K | 1 |
| Ozdemir, S; Ozmen, A; Ozturk, N; Yaras, N | 1 |
| Liang, J; Xu, X; Zhang, L | 1 |
| Gaertner, FC; Higuchi, T; Lee, M; Nekolla, SG; Pellegata, NS; Repokis, I; Robinson, S; Schwaiger, M; Wiedemann, T; Yousefi, BH; Yu, M | 1 |
| Boudoulas, H; Chalikias, G; Kapelouzou, A; Karayannakos, P; Konstantinides, S; Kostakis, A; Schäfer, K; Tentes, I; Tziakas, D | 1 |
| Hübner, N; Kazdová, L; Kurtz, TW; Landa, V; Mancini, M; Mlejnek, P; Oliyarnyk, O; Pravenec, M; Saar, K; Schulz, H; Šilhavý, J; Šimáková, M; Škop, V; Zídek, V | 1 |
| Catterall, WA; Han, S; Jones, CJ; Scheuer, T; Tai, C | 1 |
| Ayan, S; Dundar, G; Erden, Y; Gokce, G; Gultekin, EY; Korgalı, E; Yildirim, S | 1 |
| Bouvet, M; Hoffman, RM; Kaushal, S; Luiken, GA; Metildi, CA | 1 |
| Chi, J; Guo, H; Ji, Z; Jiang, C; Lv, H; Tang, W; Zhai, X; Zhao, F | 1 |
| Amodeo, DA; Jones, JH; Ragozzino, ME; Sweeney, JA | 1 |
| Kuwano, T; Miura, S; Saku, K; Shimizu, T; Tanigawa, H; Uehara, Y; Zhang, B | 1 |
| Fujita, K; Ikegawa, S; Kimura, T; Kishi, H; Morioka, M; Okada, M; Sawai, H; Tsumaki, N; Yahara, Y; Yamashita, A | 1 |
| Jasińska-Stroschein, M; Orszulak-Michalak, D; Owczarek, J; Wesołowska, A | 1 |
| Gökçe, A; Gökçe, EC; Gürer, B; Kahveci, R; Ozevren, H; Turkoglu, E | 1 |
| Adachi, O; Fukushige, S; Horii, A; Kawamoto, S; Matsuo, S; Saiki, Y | 1 |
| Fedin, AN; Kuzubova, NA; Lebedeva, ES; Titova, ON | 1 |
| Guo, M; Huang, D; Li, JB; Li, S; Wang, FB; Wei, M; Yan, ML; Yu, T | 1 |
| Amar, E; Dolkart, O; Marmor, S; Shapira, S; Steinberg, EL; Weinbroum, AA | 1 |
| Chang, CC; Chuang, CL; Hsieh, HG; Huang, HC; Lee, FY; Lee, SD; Lee, WS; Lin, HC; Wang, SS | 1 |
| Amodeo, DA; Cook, EH; Ragozzino, ME; Rivera, E; Sweeney, JA | 1 |
| Goto, T; Kohari, D; Okayama, T; Otabi, H; Toyoda, A | 1 |
| Boolell, V; Calkin, AC; Chew, C; Cooper, ME; Giunti, S; Jandeleit-Dahm, KA; Rajaram, YS; Sheehy, KJ | 1 |
| Busija, DW; Domoki, F; Gáspár, T; Katakam, PV; Mayanagi, K | 1 |
| Behrendt, M; Brandt-Eliasson, U; Forsberg, GB; Gan, LM; Grönros, J; Hansson, GI; Wikström, J | 1 |
| Alfinito, PD; Cosmi, S; Deecher, DC; Pawlyk, AC; Roman, J; Zhou, T | 1 |
| Fu, M; Hu, SJ; Mou, Y; Yang, Y | 1 |
| Deguchi, Y; Hirose, Y; Kawamura, S; Kushida, M; Nagahori, H; Nishioka, K; Okuno, Y; Sukata, T; Sumida, K; Tomigahara, Y; Uwagawa, S; Yamada, T | 1 |
| Cohen, SM; Kaneko, H; Okuno, Y; Uwagawa, S; Yamada, T | 1 |
| Azuma, CT; Marsden, AM; Orton, TC; Scott, RC; Sidaway, J; Wang, Y; Westwood, FR | 1 |
| Fiebeler, A; Haller, H; Luft, FC; Menne, J; Mervaala, EM; Muller, DN; Park, JK | 1 |
| Cunningham, KA; Fox, RG; Nic Dhonnchadha, BA; Rice, KC; Stutz, SJ | 1 |
| Badimon, L; Casaní, L; Duran, X; Juan-Babot, O; Peña, E; Vilahur, G | 1 |
| Aznar, S; Knudsen, GM; Licht, CL; Marcussen, AB; Overstreet, DH; Wegener, G | 1 |
| Corso, T; Dziewiatkowski, J; Hesse, RA; Klejbor, I; Kucinski, A; Miletich, R; Moryś, J; Rice, KC; Spodnik, JH; Stachowiak, EK; Stachowiak, MK; Wersinger, SR | 1 |
| Brown, L; Chan, V; Hoey, A; Loch, D | 1 |
| Kang, BY; Mehta, JL; Palade, P; Sharma, SG; Wang, W | 1 |
| Akgür, FM; Ateş, O; Karakaya, E; Olguner, M | 1 |
| Cai, J; Hu, X; Smith, GM; Yang, J | 1 |
| Cho, SI; Gwag, BJ; Lee, HY; Lim, HR; Moon, GJ; Noh, JS; Park, EJ; Rao, RR; Springer, JE | 1 |
| Arnt, J; Bang-Andersen, B; Brennum, LT; Grayson, B; Idris, N; Neill, J; Witten, LM | 1 |
| Anisman, H; Comps-Agrar, L; Dale, LB; Drysdale, L; Ferguson, SS; Holmes, KD; Lee, D; Magalhaes, AC; Pin, JP; Poulter, MO; Roth, BL; Yadav, PN | 1 |
| Bhandari, U; Javed, S; Kumar, V; Pathan, RA; Sharma, H | 1 |
| da Silva Torres, T; de Carvalho, JJ; Mandarim-de-Lacerda, CA; Neto-Ferreira, R; Novaes Rocha, V | 1 |
| Allen, TJ; Calkin, AC; Cooper, ME; Forbes, JM; Giunti, S; Jandeleit-Dahm, KA; Thomas, MC | 1 |
| Aragoncillo, P; Caro-Vadillo, A; Fernández-Cruz, A; Gómez-Garre, D; González-Rubio, ML; Muñoz-Pacheco, P | 1 |
| Felker, GM | 1 |
| Aikawa, M; Ganz, P; Josephson, L; Kacher, DF; Libby, P; Morishige, K; Weissleder, R | 1 |
| Albrecht, C; Bea, F; Blessing, E; Ieronimakis, N; Katus, HA; Konstandin, M; Kranzhöfer, A; Kranzhöfer, R; Morris-Rosenfeld, S; Preusch, MR; Shimizu, T; Vanakaris, A | 1 |
| Bunck, M; Gaburro, S; Hauschild, M; Landgraf, R; Sartori, SB; Singewald, N | 1 |
| Lee, S; Lim, TKY; Shi, XQ; Zhang, J; Zhao, YQ | 1 |
| Benardón, ME; Cacciamani, V; García, IM; Manucha, W; Mazzei, L | 1 |
| Aiello, VD; Casella Filho, A; Chagas, AC; da Luz, PL; Dourado, PM; Galvao, TF; Landim, MB; Mathias, W; Tsutsui, JM | 1 |
| Qian, HY; Tang, YD; Wang, H; Xu, H; Yang, YJ; Zhang, Q | 1 |
| Azure, M; Bozek, J; Broekema, M; Casebier, D; Cdebaca, M; Cesati, R; Guaraldi, M; Kagan, M; Lamoy, M; Lazewatsky, J; Mistry, M; Onthank, D; Purohit, A; Radeke, H; Robinson, SP; Silva, P; Yalamanchili, P; Yu, M | 1 |
| Arslan, S; Güler, A; Kılıçkaya, O; Onan, B; Oztaş, E; Sahin, MA; Ucak, A; Uysal, B; Yılmaz, AT | 1 |
| Ansari, JA; Bhandari, U; Haque, SE; Pillai, KK | 1 |
| Bonhaus, DW; McFarland, K; Price, DL | 1 |
| Hammond, B; Hussain, I; Kew, JN; Stean, TO; Upton, N; Virley, DJ; Waters, KA | 1 |
| Dawson, HN; Indraswari, F; James, ML; Kernagis, D; Laskowitz, DT; Lei, B; Wang, H; Warner, DS | 1 |
| Chai, HT; Chang, HW; Chang, LT; Chen, YT; Chung, SY; Ko, SF; Leu, S; Lin, KC; Sun, CK; Yen, CH; Yip, HK | 1 |
| Budinger, GR; Chiarella, SE; Gonzalez, A; Misharin, AV; Mutlu, GM; Perlman, H; Radigan, KA; Soberanes, S; Urich, D; Wunderink, RG | 1 |
| Guan, RJ; Li, JJ; Li, XL | 1 |
| Bo, H; Deng, J; Deng, W; Huang, NW; Wang, DX; Zhang, W; Zhu, T | 1 |
| Anderson, R; Carlson, G; Gandal, MJ; Gur, RE; Jonak, G; Klook, K; Leitman, V; Liang, Y; Ortinski, PI; Pierce, RC; Siegel, SJ; Sisti, J; Thieu, T | 1 |
| Antonioli, L; Aydinoglu, F; Bernardini, N; Blandizzi, C; Colucci, R; Duranti, E; Fornai, M; Ippolito, C; Rugani, I; Segnani, C; Taddei, S; Virdis, A | 1 |
| Mitsikostas, DD; Tfelt-Hansen, P | 1 |
| Bölcskei, K; Danysz, W; Dekundy, A; Dézsi, L; Gravius, A; Gyertyán, I; Hofmann, M; Horváth, C; Kordás, KS; Parsons, CG; Sághy, K; Wittko-Schneider, IM | 1 |
| Catoi, C; Clichici, S; Dudea, M; Filip, A; Mircea, PA; Muresan, A; Nagy, A; Olteanu, D | 1 |
| Diaz, JA; Hawley, AE; Lawrence, DA; Myers, DD; Patterson, KA; Wakefield, TW; Wrobleski, SK; Zhang, X | 1 |
| Chello, M; Spadaccio, C | 1 |
| Aeed, H; Bruck, R; Gavish, D; Sharvit, E; Shirin, H | 1 |
| Gibson, MF; Gibson, TM; Jones, SP; Lefer, DJ; Rimmer, DM; Sharp, BR | 1 |
| Böhm, M; Dirnagl, U; Endres, M; Laufs, U; Nickenig, G; Priller, J; Werner, N | 1 |
| Brunet, J; Fernandes, JC; Flory, C; Martel-Pelletier, J; Moldovan, F; Pelletier, JP; Schrier, D | 1 |
| Rimmerman, N; Weiner, I; Zuckerman, L | 1 |
| Cameron, N; Cotter, M; Inkster, M; Nangle, M | 1 |
| Burroughs, K; Cosmi, S; Deecher, DC; Johnston, GH; Leventhal, L; Sipe, K | 1 |
| Busso, N; Chobaz, V; Gabay, C; Palmer, G; So, A; Talabot-Ayer, D; Taylor, S | 1 |
| Kaiser, K; Konstantinides, S; Schäfer, K | 1 |
| Bauersachs, J; Eigenthaler, M; Ertl, G; Firnschild, A; Fraccarollo, D; Frantz, S; Schäfer, A; Tas, P | 1 |
| Adeli, K; Cheung, RC; Chong, T; Federico, L; Naples, M; Smith, GJ; Taylor, D | 1 |
| Chen, J; Li, D; Mehta, JL; Schaefer, R | 1 |
| Mathiasen, L; Mirza, NR | 1 |
| Mareev, VIu | 1 |
| Doerfler, A; Engelhorn, T; Heusch, G; Schulz, R | 1 |
| Carlsson, MA; Fätkenheuer, G; Furuhashi, M; Heldin, CH; Kappert, K; Leppänen, O; Ostman, A; Paulsson, J; Rosenkranz, S | 1 |
| Cho, SI; Gwag, BJ; Joo, IS; Kim, KW; Lee, JK; Lee, YA; Lim, HR; Noh, JS; Shin, JH | 1 |
| Habibi, J; Hayden, MR; Morris, EM; Rehmer, N; Sowers, JR; Stump, CS; Wei, Y; Whaley-Connell, AT; Yaghoubian, JC | 1 |
| Bulhak, A; Hedin, U; Pernow, J; Roy, J; Sjöquist, PO | 1 |
| Bellosta, S; Camera, M; Canavesi, M; Corsini, A; Monetti, M; Paoletti, R; Parente, R; Tremoli, E | 1 |
| Herman, D; Mei, Y; Sun, S; Xing, H | 1 |
| Adam, O; Böhm, M; Custodis, F; Frost, G; Laufs, U; Schäfers, HJ; Sussman, MA | 1 |
| Benigni, A; Carrara, F; Cattaneo, D; Corna, D; Gaspari, F; Perico, N; Remuzzi, A; Remuzzi, G; Sangalli, F; Zoja, C | 1 |
| Adeli, K; Federico, LM; Naples, M; Nelken, J; Xu, E | 1 |
| Askew, V; Auerbach, B; Dillon, L; Hanselman, JC; Kennedy, RM; Kowala, MC; Larsen, SD; Lin, Z; Lu, GH; Miller, S; Park, WK; Robertson, A; Roth, BD; Sekerke, C; Song, Y; Steinbaugh, BA; Sun, K; Tait, BD; Trivedi, BK | 1 |
| Balkaya, M; Endres, M; Gertz, K; Kronenberg, G; Laufs, U; Leithner, C; Lindauer, U; Prinz, V | 1 |
| Ahmadi, S; Brockhaus, J; Brune, K; Fritschy, JM; Hess, A; Hösl, K; Knabl, J; Möhler, H; Reinold, H; Rudolph, U; Sergejeva, M; Witschi, R; Zeilhofer, HU; Zeilhofer, UB | 1 |
| Kawachi, H; Khadzhynov, D; Krämer, S; Kron, S; Loof, T; Martini, S; Morgera, S; Neumayer, HH; Peters, H; Shimizu, F; Wang-Rosenke, Y | 1 |
| Coppey, LJ; Davidson, EP; Kleinschmidt, TL; Lund, DD; Oltman, CL; Yorek, MA | 1 |
| Ichihara, K; Itagaki, M; Kano, S; Satoh, K; Takaguri, A | 1 |
| Boulanger, M; Della-Zuana, O; Duhault, J; Espinal, J; Lacour, F; Ravel, D; Wierzbicki, M | 1 |
| Barthelemy, G; Bernat, A; Dol, F; Herbert, JM; Rinaldi, M | 1 |
| Carlsson, ML | 1 |
| Branchek, TA; Calligaro, DO; Flaugh, ME; Gilbert, PJ; Johnson, KW; Kiefer, AD; Mancuso, V; Nelson, DL; Phebus, LA; Van Belle, K; Zgombick, JM | 1 |
| Artru, AA; Karpas, Z; Lam, MA; Lorber, A; Mueller, LA; Roytblat, L; Shapira, Y | 1 |
| Fischer, G; Grohs, JG; Raberger, G | 1 |
3 review(s) available for fluorobenzenes and Disease Models, Animal
| Article | Year |
|---|---|
Targeting to 5-HT1F receptor subtype for migraine treatment: lessons from the past, implications for the future.
Topics: Animals; Benzamides; Carbazoles; Clinical Trials as Topic; Disease Models, Animal; Drug Evaluation, Preclinical; Fatigue; Fluorobenzenes; Humans; Indoles; Migraine Disorders; Models, Neurological; Molecular Targeted Therapy; Nausea; Paresthesia; Pilot Projects; Piperidines; Pyridines; Randomized Controlled Trials as Topic; Receptor, Serotonin, 5-HT1F; Receptors, Serotonin; Serotonin; Serotonin Receptor Agonists; Treatment Outcome; Vertigo | 2012 |
Looking to the future: diabetic neuropathy and effects of rosuvastatin on neurovascular function in diabetes models.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Disease Models, Animal; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Neural Conduction; Pyrimidines; Rats; Regional Blood Flow; Rosuvastatin Calcium; Sciatic Nerve; Sulfonamides; Vasodilation | 2003 |
[Treatment of chronic heart failure. The time of statins?].
Topics: Aged; Animals; Anticholesteremic Agents; Cholesterol; Controlled Clinical Trials as Topic; Costs and Cost Analysis; Disease Models, Animal; Female; Fluorobenzenes; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Male; Prognosis; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Time Factors | 2005 |
114 other study(ies) available for fluorobenzenes and Disease Models, Animal
| Article | Year |
|---|---|
Enhancing neuronal chloride extrusion rescues α2/α3 GABA
Topics: Analgesia; Analgesics; Animals; Brain-Derived Neurotrophic Factor; Chlorides; Disease Models, Animal; Fluorobenzenes; GABA-A Receptor Agonists; Ion Transport; K Cl- Cotransporters; Ligands; Male; Neuralgia; Neurons; Peripheral Nerve Injuries; Rats; Rats, Sprague-Dawley; Receptor, trkB; Receptors, GABA-A; Symporters; Synapses; Triazoles | 2020 |
Biological assessment of new tetrahydroacridine derivatives with fluorobenzoic moiety in vitro on A549 and HT-29 cell lines and in vivo on animal model.
Topics: Acridines; Animals; Cell Line, Tumor; Colorectal Neoplasms; Disease Models, Animal; Fluorobenzenes; Humans; Hyaluronoglucosaminidase; Lethal Dose 50; Lung Neoplasms; Mice; Rats; Toxicity Tests | 2020 |
Analysis of the effects of a tricyclic antidepressant on secondary sleep disturbance induced by chronic pain in a preclinical model.
Topics: Amitriptyline; Animals; Antidepressive Agents, Tricyclic; Chronic Pain; Disease Models, Animal; Fluorobenzenes; Male; Mice; Neuralgia; Piperidines; Receptor, Serotonin, 5-HT2A; Serotonin 5-HT2 Receptor Antagonists; Sleep Wake Disorders | 2020 |
Investigating the role of 5-HT2A and 5-HT2C receptor activation in the effects of psilocybin, DOI, and citalopram on marble burying in mice.
Topics: Aminopyridines; Amphetamines; Animals; Behavior, Animal; Citalopram; Compulsive Behavior; Disease Models, Animal; Female; Fluorobenzenes; Indoles; Mice; Piperidines; Psilocybin; Receptor, Serotonin, 5-HT2A; Receptor, Serotonin, 5-HT2C; Selective Serotonin Reuptake Inhibitors; Serotonin 5-HT2 Receptor Agonists; Serotonin Antagonists | 2021 |
16p11.2 deletion syndrome mice perseverate with active coping response to acute stress - rescue by blocking 5-HT2A receptors.
Topics: Adaptation, Psychological; Animals; Autistic Disorder; Behavior, Animal; Chromosome Deletion; Chromosome Disorders; Chromosomes, Human, Pair 16; Disease Models, Animal; Fluorobenzenes; Intellectual Disability; Male; Mice; Piperidines; Receptor, Serotonin, 5-HT2A; Serotonin; Serotonin 5-HT2 Receptor Antagonists; Stress, Psychological | 2017 |
Effects of ralfinamide in models of nerve injury and chemotherapy-induced neuropathic pain.
Topics: Amines; Analgesics; Animals; Antineoplastic Agents; Blood Pressure; Cyclohexanecarboxylic Acids; Disease Models, Animal; Fluorobenzenes; Gabapentin; gamma-Aminobutyric Acid; Heart Rate; Locomotion; Male; Neuralgia; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Peripheral Nervous System; Rats; Rats, Sprague-Dawley | 2018 |
Regulatory T cells contribute to rosuvastatin-induced cardioprotection against ischemia-reperfusion injury.
Topics: Animals; Cardiotonic Agents; Disease Models, Animal; Fluorobenzenes; Forkhead Transcription Factors; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mevalonic Acid; Myocardial Ischemia; Myocardial Reperfusion Injury; Pyrimidines; Rats; Rats, Wistar; Rosuvastatin Calcium; Sulfonamides; T-Lymphocytes, Regulatory; Troponin I | 2013 |
Rosuvastatin in experimental brain trauma: improved capillary patency but no effect on edema or cerebral blood flow.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Blood-Brain Barrier; Brain Edema; Brain Injuries; Capillaries; Cerebrovascular Circulation; Disease Models, Animal; Edetic Acid; Epoprostenol; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Microcirculation; Nitric Oxide; Pyrimidines; Rats; Rats, Sprague-Dawley; Rosuvastatin Calcium; Sulfonamides; Time Factors | 2013 |
HMGCoA reductase inhibition reverses myocardial fibrosis and diastolic dysfunction through AMP-activated protein kinase activation in a mouse model of metabolic syndrome.
Topics: Actins; AMP-Activated Protein Kinases; Animals; Cells, Cultured; Collagen Type I; Diastole; Disease Models, Animal; Enzyme Activation; Fibroblasts; Fibrosis; Fluorobenzenes; Heart Diseases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leptin; Metabolic Syndrome; Mice; Mice, Inbred C57BL; Mice, Knockout; Myocardium; Procollagen; Pyrimidines; Rats; Receptors, LDL; Recovery of Function; Rosuvastatin Calcium; Signal Transduction; Sulfonamides; Time Factors; Transfection; Transforming Growth Factor beta1; Ventricular Function, Left; Ventricular Remodeling | 2013 |
Role of serotonin 5-HT2A receptors in the development of cardiac hypertrophy in response to aortic constriction in mice.
Topics: Age Factors; Analysis of Variance; Animals; Aorta; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Cardiomegaly; Constriction, Pathologic; Disease Models, Animal; Echocardiography; Fluorobenzenes; Gene Expression Regulation; Hemodynamics; Histone Deacetylases; Male; Mice; Mice, Inbred C57BL; Myocardium; Piperidines; Receptor, Serotonin, 5-HT2A; RNA, Messenger; Serotonin Antagonists | 2013 |
Pretreatment with rosuvastatin protects against focal cerebral ischemia/reperfusion injury in rats through attenuation of oxidative stress and inflammation.
Topics: Animals; Brain Infarction; Brain Ischemia; Calcium-Binding Proteins; Cyclooxygenase 2; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Ectodysplasins; Encephalitis; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Membrane Glycoproteins; Microfilament Proteins; NADPH Oxidase 2; NADPH Oxidases; NF-kappa B; Nitric Oxide Synthase Type II; Oxidative Stress; Pyrimidines; Rats; Rats, Sprague-Dawley; Reperfusion Injury; Rosuvastatin Calcium; Sulfonamides; Up-Regulation | 2013 |
Long-term administration of rosuvastatin prevents contractile and electrical remodelling of diabetic rat heart.
Topics: Animals; Calcium; Calcium Channels, L-Type; Diabetes Mellitus, Experimental; Disease Models, Animal; Fluorobenzenes; Heart; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocardium; Myocytes, Cardiac; Pyrimidines; Rats; Rats, Wistar; rhoA GTP-Binding Protein; Rosuvastatin Calcium; Sarcoplasmic Reticulum; Sulfonamides | 2013 |
Rosuvastatin prevents pressure overload‑induced myocardial hypertrophy via inactivation of the Akt, ERK1/2 and GATA4 signaling pathways in rats.
Topics: Animals; Cardiomegaly; Disease Models, Animal; Electrocardiography; Fluorobenzenes; GATA4 Transcription Factor; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mitogen-Activated Protein Kinase 3; Myocytes, Cardiac; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyrimidines; Rats; Rosuvastatin Calcium; Signal Transduction; Sulfonamides | 2013 |
Preclinical evaluation of 18F-LMI1195 for in vivo imaging of pheochromocytoma in the MENX tumor model.
Topics: Adrenal Gland Neoplasms; Animals; Autoradiography; Disease Models, Animal; Feasibility Studies; Fluorine Radioisotopes; Fluorobenzenes; Gene Expression Regulation, Neoplastic; Guanidines; Multiple Endocrine Neoplasia; Mutation; Norepinephrine Plasma Membrane Transport Proteins; Organ Size; Pheochromocytoma; Positron-Emission Tomography; Rats; Tumor Burden | 2013 |
Erythrocyte membrane cholesterol and lipid core growth in a rabbit model of atherosclerosis: modulatory effects of rosuvastatin.
Topics: Animals; Atherosclerosis; Cholesterol; Diet, Atherogenic; Disease Models, Animal; Erythrocyte Membrane; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Plaque, Atherosclerotic; Pyrimidines; Rabbits; Rosuvastatin Calcium; Sulfonamides | 2013 |
Rosuvastatin can block pro-inflammatory actions of transgenic human C-reactive protein without reducing its circulating levels.
Topics: Animals; Anti-Inflammatory Agents; C-Reactive Protein; Disease Models, Animal; Fluorobenzenes; Gene Expression Regulation; Humans; Inflammation; Inflammation Mediators; Interleukin-6; Liver; Male; Myocytes, Cardiac; Oxidative Stress; Pyrimidines; Rats; Rats, Inbred SHR; Rats, Transgenic; Rosuvastatin Calcium; Sulfonamides; Tumor Necrosis Factor-alpha | 2014 |
Enhancement of inhibitory neurotransmission by GABAA receptors having α2,3-subunits ameliorates behavioral deficits in a mouse model of autism.
Topics: Animals; Autistic Disorder; Behavior, Animal; Benzodiazepines; Brain; Disease Models, Animal; Fluorobenzenes; Interpersonal Relations; Male; Mice; Mice, 129 Strain; Mice, Inbred C57BL; Protein Subunits; Pyridines; Receptors, GABA-A; Social Behavior; Synaptic Transmission; Triazoles; Zolpidem | 2014 |
In-vitro effects of PDE5 inhibitor and statin treatment on the contractile responses of experimental MetS rabbit's cavernous smooth muscle.
Topics: Animals; Disease Models, Animal; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Male; Metabolic Syndrome; Muscle Contraction; Muscle Relaxation; Myocytes, Smooth Muscle; Penis; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Pyrimidines; Rabbits; Rosuvastatin Calcium; Sildenafil Citrate; Sulfonamides; Sulfones | 2014 |
Advantages of fluorescence-guided laparoscopic surgery of pancreatic cancer labeled with fluorescent anti-carcinoembryonic antigen antibodies in an orthotopic mouse model.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Neoplasm; Carcinoembryonic Antigen; Cell Line, Tumor; Disease Models, Animal; Disease-Free Survival; Female; Fluorescent Dyes; Fluorobenzenes; Humans; Laparoscopy; Logistic Models; Mice; Mice, Nude; Neoplasm Recurrence, Local; Neoplasm Transplantation; Optical Imaging; Pancreatectomy; Pancreatic Neoplasms; Random Allocation; Treatment Outcome; Tumor Burden | 2014 |
Yellow wine polyphenolic compounds inhibit matrix metalloproteinase-2, -9 expression and improve atherosclerotic plaque in LDL-receptor-knockout mice.
Topics: Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Mice, Inbred C57BL; Mice, Knockout; Oryza; Plaque, Atherosclerotic; Polyphenols; Pyrimidines; Receptors, LDL; Rosuvastatin Calcium; Sulfonamides; Tissue Inhibitor of Metalloproteinase-1; Tissue Inhibitor of Metalloproteinase-2; Wine | 2014 |
Risperidone and the 5-HT2A receptor antagonist M100907 improve probabilistic reversal learning in BTBR T + tf/J mice.
Topics: Animals; Antipsychotic Agents; Autistic Disorder; Disease Models, Animal; Fluorobenzenes; Male; Mice; Mice, Inbred C57BL; Mice, Inbred Strains; Piperidines; Probability Learning; Receptor, Serotonin, 5-HT2A; Reversal Learning; Risperidone; Serotonin 5-HT2 Receptor Antagonists | 2014 |
Rosuvastatin activates ATP-binding cassette transporter A1-dependent efflux ex vivo and promotes reverse cholesterol transport in macrophage cells in mice fed a high-fat diet.
Topics: Animals; Apolipoprotein A-I; Atherosclerosis; Atorvastatin; ATP Binding Cassette Transporter 1; Biological Transport; Cell Line; Cholesterol Esters; Cholesterol, Dietary; Cholesterol, HDL; Cholesterol, VLDL; Diet, High-Fat; Disease Models, Animal; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Macrophages; Male; Mice; Mice, Inbred C57BL; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Time Factors | 2014 |
Statin treatment rescues FGFR3 skeletal dysplasia phenotypes.
Topics: Achondroplasia; Animals; Bone Development; Cartilage; Cell Differentiation; Chondrocytes; Disease Models, Animal; Female; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Induced Pluripotent Stem Cells; Lovastatin; Male; Mice; Mice, Inbred C57BL; Phenotype; Pyrimidines; Receptor, Fibroblast Growth Factor, Type 3; Rosuvastatin Calcium; Sulfonamides; Thanatophoric Dysplasia | 2014 |
Rosuvastatin, sildenafil and their combination in monocrotaline-induced pulmonary hypertension in rat.
Topics: Animals; Antihypertensive Agents; Arterial Pressure; Biomarkers; Cholesterol, HDL; Disease Models, Animal; Drug Therapy, Combination; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Male; Monocrotaline; Natriuretic Peptide, Brain; Phosphodiesterase 5 Inhibitors; Piperazines; Pulmonary Artery; Purines; Pyrimidines; Rats, Wistar; Rosuvastatin Calcium; Sildenafil Citrate; Sulfonamides; Time Factors; Vascular Endothelial Growth Factor A; Vascular Remodeling; Vasodilator Agents; Ventricular Function, Right; Ventricular Pressure | 2014 |
Evaluation of topical application and systemic administration of rosuvastatin in preventing epidural fibrosis in rats.
Topics: Administration, Topical; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cicatrix; Disease Models, Animal; Epidural Space; Fibrosis; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intubation, Gastrointestinal; Laminectomy; Male; Pyrimidines; Rats; Rats, Wistar; Rosuvastatin Calcium; Sulfonamides; Transforming Growth Factor beta1 | 2015 |
Single-dose rosuvastatin ameliorates lung ischemia-reperfusion injury via upregulation of endothelial nitric oxide synthase and inhibition of macrophage infiltration in rats with pulmonary hypertension.
Topics: Animals; Anti-Inflammatory Agents; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Disease Models, Animal; Endothelium, Vascular; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Pulmonary; Lung; Lung Injury; Macrophages; Male; Mevalonic Acid; Monocrotaline; Nitric Oxide Synthase Type III; Oxygen; Phosphorylation; Pulmonary Edema; Pyrimidines; Rats, Sprague-Dawley; Reperfusion Injury; Rosuvastatin Calcium; Sulfonamides; Up-Regulation | 2015 |
[Effect of endotelioprotectors on the tone of pulmonary arteries and bronchi in the model of obstructive lung pathology].
Topics: Animals; Bronchi; Disease Models, Animal; Endothelium, Vascular; Fluorobenzenes; Glycosaminoglycans; Male; Muscle Contraction; Muscle, Smooth, Vascular; Nitrogen Dioxide; Protective Agents; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pyrimidines; Rats; Rats, Wistar; Rosuvastatin Calcium; Sulfonamides; Vasodilation | 2014 |
Effect of combined treatment with rosuvastatin and protein kinase Cβ2 inhibitor on angiogenesis following myocardial infarction in diabetic rats.
Topics: Animals; Diabetes Mellitus, Experimental; Disease Models, Animal; Drug Therapy, Combination; Fibrosis; Fluorobenzenes; Human Umbilical Vein Endothelial Cells; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoxia-Inducible Factor 1, alpha Subunit; Male; Myocardial Infarction; Neovascularization, Physiologic; Nitric Oxide Synthase Type III; Phosphorylation; Protein Kinase C beta; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrimidines; Rats; Rosuvastatin Calcium; Sulfonamides; Vascular Endothelial Growth Factor A | 2015 |
Protective effects of rosuvastatin in a rat model of lung contusion: Stimulation of the cyclooxygenase 2-prostaglandin E-2 pathway.
Topics: Acute Lung Injury; Animals; Bronchoalveolar Lavage Fluid; Contusions; Cyclooxygenase 2; Dinoprostone; Disease Models, Animal; Drug Evaluation, Preclinical; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lung; Male; Meloxicam; Pyrimidines; Random Allocation; Rats; Rosuvastatin Calcium; Sulfonamides; Thiazines; Thiazoles | 2015 |
Rosuvastatin improves hepatopulmonary syndrome through inhibition of inflammatory angiogenesis of lung.
Topics: Administration, Oral; Animals; Disease Models, Animal; Down-Regulation; Fluorobenzenes; Hemodynamics; Hepatopulmonary Syndrome; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Lung; Male; Neovascularization, Pathologic; Pyrimidines; Rats; Rats, Sprague-Dawley; Reference Values; Rosuvastatin Calcium; Sulfonamides; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A | 2015 |
5HT
Topics: Animals; Autism Spectrum Disorder; Autistic Disorder; Cognition Disorders; Corpus Striatum; Disease Models, Animal; Exploratory Behavior; Fluorobenzenes; Grooming; Male; Mice; Mice, Inbred Strains; Neostriatum; Piperidines; Prefrontal Cortex; Receptor, Serotonin, 5-HT2A; Reversal Learning; Serotonin 5-HT2 Receptor Antagonists; Stereotyped Behavior | 2017 |
The acute social defeat stress and nest-building test paradigm: A potential new method to screen drugs for depressive-like symptoms.
Topics: Animals; Depression; Disease Models, Animal; Dominance-Subordination; Fluorobenzenes; Fluoxetine; Male; Mice; Mice, Inbred C57BL; Nesting Behavior; Phenols; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists; Stress, Psychological | 2017 |
The HMG-CoA reductase inhibitor rosuvastatin and the angiotensin receptor antagonist candesartan attenuate atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes via effects on advanced glycation, oxidative stress and inflammation.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apolipoproteins E; Benzimidazoles; Biphenyl Compounds; Blood Vessels; Diabetes Mellitus; Disease Models, Animal; Fluorobenzenes; Glycation End Products, Advanced; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Mice; Mice, Inbred C57BL; Mice, Knockout; Oxidative Stress; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Tetrazoles | 2008 |
Acute treatment with rosuvastatin protects insulin resistant (C57BL/6J ob/ob) mice against transient cerebral ischemia.
Topics: Animals; Blood Glucose; Blotting, Western; Cerebrovascular Circulation; Cholesterol; Disease Models, Animal; Endothelium, Vascular; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Insulin Resistance; Ischemic Attack, Transient; Laser-Doppler Flowmetry; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Nitric Oxide Synthase; Obesity; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Rosuvastatin Calcium; Sulfonamides; Time Factors | 2008 |
Effects of rosuvastatin on cardiovascular morphology and function in an ApoE-knockout mouse model of atherosclerosis.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Biomarkers; Blood Flow Velocity; Brachiocephalic Trunk; Coronary Circulation; Coronary Vessels; Disease Models, Animal; Disease Progression; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Lipids; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Pyrimidines; Regional Blood Flow; Rosuvastatin Calcium; Sulfonamides; Time Factors; Ultrasonography | 2008 |
Simultaneous telemetric monitoring of tail-skin and core body temperature in a rat model of thermoregulatory dysfunction.
Topics: Adrenergic alpha-Agonists; Animals; Body Temperature; Body Temperature Regulation; Clonidine; Disease Models, Animal; Estradiol; Estrogens; Female; Fluorobenzenes; Monitoring, Physiologic; Ovariectomy; Piperidines; Rats; Rats, Sprague-Dawley; Serotonin Antagonists; Skin Temperature; Tail; Telemetry; Time Factors | 2009 |
Beneficial effect of rosuvastatin on cardiac dysfunction is associated with alterations in calcium-regulatory proteins.
Topics: Animals; Calcium-Binding Proteins; Disease Models, Animal; Fluorobenzenes; Heart; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-10; Interleukin-6; Male; Organ Size; Pyrimidines; Rats; Rats, Sprague-Dawley; Rosuvastatin Calcium; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Sulfonamides; Ventricular Remodeling | 2009 |
Mode of action analysis for the synthetic pyrethroid metofluthrin-induced rat liver tumors: evidence for hepatic CYP2B induction and hepatocyte proliferation.
Topics: Animals; Apoptosis; Aryl Hydrocarbon Hydroxylases; Cell Proliferation; Constitutive Androstane Receptor; Cyclopropanes; Cytochrome P-450 CYP2B1; Disease Models, Animal; Female; Fluorobenzenes; Gene Expression Regulation, Neoplastic; Liver; Liver Neoplasms, Experimental; Male; Microsomes, Liver; Oligonucleotide Array Sequence Analysis; Oxidative Stress; Phenobarbital; Pyrethrins; Rats; Rats, Wistar; Receptors, Cytoplasmic and Nuclear; RNA Interference; Statistics, Nonparametric | 2009 |
Case study: an evaluation of the human relevance of the synthetic pyrethroid metofluthrin-induced liver tumors in rats based on mode of action.
Topics: Animals; Cell Proliferation; Constitutive Androstane Receptor; Cyclopropanes; Cytochrome P-450 Enzyme System; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Liver; Liver Neoplasms, Experimental; Male; Organ Size; Phenobarbital; Pyrethrins; Rats; Rats, Wistar; Receptors, Cytoplasmic and Nuclear; Risk Assessment; Species Specificity; Time Factors | 2009 |
Statin-induced myopathy in the rat: relationship between systemic exposure, muscle exposure and myopathy.
Topics: Animals; Disease Models, Animal; Female; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Muscle, Skeletal; Muscular Diseases; Pyridines; Pyrimidines; Rats; Rats, Wistar; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2009 |
Rosuvastatin protects against angiotensin II-induced renal injury in a dose-dependent fashion.
Topics: Albuminuria; Angiotensin II; Animals; Blood Pressure; Collagen Type IV; Disease Models, Animal; Dose-Response Relationship, Drug; Fibronectins; Fluorescent Antibody Technique, Indirect; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Immunohistochemistry; Inflammation; Intercellular Adhesion Molecule-1; Kidney; Kidney Cortex; Kidney Medulla; Male; Monocytes; Necrosis; Neutrophil Infiltration; Nitric Oxide Synthase Type II; Pyrimidines; Rats; Rats, Sprague-Dawley; Rats, Transgenic; Rosuvastatin Calcium; Sulfonamides | 2009 |
Blockade of the serotonin 5-HT2A receptor suppresses cue-evoked reinstatement of cocaine-seeking behavior in a rat self-administration model.
Topics: Analysis of Variance; Animals; Cocaine; Cocaine-Related Disorders; Conditioning, Operant; Cues; Disease Models, Animal; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Extinction, Psychological; Fluorobenzenes; Food Deprivation; Male; Piperidines; Rats; Rats, Sprague-Dawley; Self Administration; Serotonin 5-HT2 Receptor Antagonists; Serotonin Antagonists | 2009 |
Induction of RISK by HMG-CoA reductase inhibition affords cardioprotection after myocardial infarction.
Topics: Animals; bcl-2-Associated X Protein; Caspase 3; Disease Models, Animal; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; Proto-Oncogene Proteins c-akt; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2009 |
The brain 5-HT4 receptor binding is down-regulated in the Flinders Sensitive Line depression model and in response to paroxetine administration.
Topics: Animals; Antidepressive Agents, Second-Generation; Autoradiography; Brain; Citalopram; Depression; Disease Models, Animal; Fenclonine; Fenfluramine; Fluorobenzenes; Freezing Reaction, Cataleptic; Male; Paroxetine; Piperidines; Protein Binding; Rats; Rats, Inbred Strains; Rats, Sprague-Dawley; Receptors, Serotonin, 5-HT4; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Antagonists; Serotonin Plasma Membrane Transport Proteins; Swimming; Time Factors; Tritium | 2009 |
Serotonergic hyperinnervation and effective serotonin blockade in an FGF receptor developmental model of psychosis.
Topics: Animals; Animals, Newborn; Antipsychotic Agents; Behavior, Animal; Disease Models, Animal; Exploratory Behavior; Female; Fluorobenzenes; Gait Disorders, Neurologic; Grooming; Hydroxyindoleacetic Acid; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Neural Inhibition; Piperidines; Protein-Tyrosine Kinases; Psychotic Disorders; Rats; Receptors, Fibroblast Growth Factor; Reflex, Startle; Serotonin; Serotonin Antagonists; Social Behavior | 2009 |
Rosuvastatin attenuates heart failure and cardiac remodelling in the ageing spontaneously hypertensive rat.
Topics: Aging; Animals; Blood Pressure; Diastole; Disease Models, Animal; Echocardiography; Fluorobenzenes; Heart; Heart Failure; Hypertension; Lipoproteins, LDL; Male; Pyrimidines; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Rats, Wistar; Rosuvastatin Calcium; Sulfonamides; Systole; Ventricular Remodeling | 2009 |
Cardiac hypertrophy during hypercholesterolemia and its amelioration with rosuvastatin and amlodipine.
Topics: Amlodipine; Animals; Blood Pressure; Body Weight; Calcium Channel Blockers; Cardiomegaly; Cholesterol, Dietary; Disease Models, Animal; Drug Therapy, Combination; Fluorobenzenes; Gene Expression; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Male; Mice; Mice, Knockout; Pyrimidines; Receptors, LDL; Reverse Transcriptase Polymerase Chain Reaction; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2009 |
Rosuvastatin protects tissue perfusion in the experimental testicular torsion model.
Topics: Animals; Disease Models, Animal; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrimidines; Rats; Rats, Wistar; Reperfusion Injury; Rosuvastatin Calcium; Spermatic Cord Torsion; Sulfonamides | 2010 |
Sensory axon targeting is increased by NGF gene therapy within the lesioned adult femoral nerve.
Topics: Analysis of Variance; Animals; Calcitonin Gene-Related Peptide; CD4 Antigens; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Female; Femoral Neuropathy; Fluorobenzenes; Ganglia, Spinal; Genetic Therapy; Genetic Vectors; Green Fluorescent Proteins; Leukocyte Common Antigens; Nerve Growth Factor; Nerve Regeneration; Rats; Rats, Sprague-Dawley; Sensory Receptor Cells; Stilbamidines; Time Factors | 2010 |
The functional and neuroprotective actions of Neu2000, a dual-acting pharmacological agent, in the treatment of acute spinal cord injury.
Topics: Acute Disease; Animals; Antioxidants; Benzoates; Disease Models, Animal; Drug Administration Schedule; Female; Fluorobenzenes; Free Radicals; meta-Aminobenzoates; Mitochondria; Motor Activity; Neuroprotective Agents; Neurotoxins; Oxidative Stress; Rats; Rats, Long-Evans; Recovery of Function; Salicylates; Spinal Cord; Spinal Cord Injuries; Treatment Outcome | 2010 |
Sertindole improves sub-chronic PCP-induced reversal learning and episodic memory deficits in rodents: involvement of 5-HT(6) and 5-HT (2A) receptor mechanisms.
Topics: Animals; Antipsychotic Agents; Cognition Disorders; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Imidazoles; Indoles; Memory Disorders; Phencyclidine; Piperidines; Quinolines; Rats; Receptor, Serotonin, 5-HT2A; Receptors, Serotonin; Reversal Learning; Schizophrenia; Sulfones | 2010 |
CRF receptor 1 regulates anxiety behavior via sensitization of 5-HT2 receptor signaling.
Topics: Amphetamines; Animals; Anxiety; Behavior, Animal; Biotinylation; Cells, Cultured; Corticotropin-Releasing Hormone; Cyclic AMP; Disease Models, Animal; Dose-Response Relationship, Drug; Embryo, Mammalian; Fluorobenzenes; Hormones; Humans; Inositol Phosphates; Ionophores; Male; Maze Learning; Mice; Monensin; Mutation; Neurons; Piperidines; Prefrontal Cortex; Rats; Reaction Time; Receptors, Corticotropin-Releasing Hormone; Receptors, Serotonin, 5-HT2; Serotonin; Serotonin 5-HT2 Receptor Agonists; Serotonin 5-HT2 Receptor Antagonists; Serotonin Agents; Signal Transduction; Transfection | 2010 |
Anti-apoptotic potential of rosuvastatin pretreatment in murine model of cardiomyopathy.
Topics: Animals; Apoptosis; Cardiomyopathies; Cardiotonic Agents; Disease Models, Animal; Doxorubicin; Fluorobenzenes; Male; Pyrimidines; Rats; Rats, Wistar; Rosuvastatin Calcium; Sulfonamides | 2011 |
Beneficial effects of rosuvastatin on aortic adverse remodeling in nitric oxide-deficient rats.
Topics: Animals; Aorta, Thoracic; Blood Pressure; Disease Models, Animal; Endothelial Cells; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Immunohistochemistry; Lipids; Microscopy, Electron, Transmission; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase Type III; Pyrimidines; Rats; Rats, Wistar; Rosuvastatin Calcium; Sulfonamides; Tunica Intima | 2011 |
The pleiotropic actions of rosuvastatin confer renal benefits in the diabetic Apo-E knockout mouse.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apolipoproteins E; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Disease Models, Animal; Drug Therapy, Combination; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Lipid Metabolism; Male; Mice; Mice, Knockout; Oxidative Stress; Pyrimidines; Rosuvastatin Calcium; Streptozocin; Sulfonamides; Tetrazoles | 2010 |
Rosuvastatin added to standard heart failure therapy improves cardiac remodelling in heart failure rats with preserved ejection fraction.
Topics: Animals; Blood Pressure; Disease Models, Animal; Echocardiography, Doppler, Color; Fluorobenzenes; Follow-Up Studies; Heart Failure; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pilot Projects; Pyrimidines; Rats; Rats, Inbred SHR; Rosuvastatin Calcium; Stroke Volume; Sulfonamides; Treatment Outcome; Ventricular Remodeling | 2010 |
Coenzyme Q10 and statins in heart failure: the dog that didn't bark.
Topics: Animals; Biomarkers; Disease Models, Animal; Dogs; Fluorobenzenes; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Ubiquinone | 2010 |
High-resolution magnetic resonance imaging enhanced with superparamagnetic nanoparticles measures macrophage burden in atherosclerosis.
Topics: Animals; Aorta, Abdominal; Atherosclerosis; Cholesterol, Dietary; Disease Models, Animal; Disease Progression; Ferrosoferric Oxide; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Macrophages; Magnetic Resonance Imaging; Male; Metal Nanoparticles; Nanoparticles; Pyrimidines; Rabbits; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2010 |
Rosuvastatin reduces neointima formation in a rat model of balloon injury.
Topics: Animals; Carotid Arteries; Catheterization; Disease Models, Animal; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Matrix Metalloproteinase 9; Neointima; Pyrimidines; Rats; Rats, Sprague-Dawley; Rosuvastatin Calcium; Sulfonamides | 2010 |
Enhanced fear expression in a psychopathological mouse model of trait anxiety: pharmacological interventions.
Topics: Animals; Anti-Anxiety Agents; Anxiety Disorders; Behavior, Animal; Corticosterone; Disease Models, Animal; Disease Progression; Drug Evaluation, Preclinical; Expressed Emotion; Fear; Fluorobenzenes; Male; Mice; Neurokinin-1 Receptor Antagonists; Phobic Disorders; Physical Conditioning, Animal; Piperidines; Psychopathology; Triazoles; Up-Regulation | 2011 |
Statins alleviate experimental nerve injury-induced neuropathic pain.
Topics: Analysis of Variance; Animals; Cholesterol; Disease Models, Animal; Dose-Response Relationship, Drug; Fluorobenzenes; Functional Laterality; Glial Fibrillary Acidic Protein; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperalgesia; Interleukin-1beta; Male; Mice; Mice, Inbred C57BL; Microglia; Neuralgia; Pain Measurement; Pain Threshold; Pyrimidines; Rats; Rats, Sprague-Dawley; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2011 |
WT-1 mRNA expression is modulated by nitric oxide availability and Hsp70 interaction after neonatal unilateral ureteral obstruction.
Topics: Animals; Animals, Newborn; Apoptosis; Cell Line; Disease Models, Animal; Dogs; Enzyme Inhibitors; Epithelial Cells; Female; Fluorobenzenes; HSP70 Heat-Shock Proteins; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Luminol; Male; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase Type II; Oligopeptides; Pyrimidines; Rats; Rats, Inbred WKY; Rosuvastatin Calcium; Sulfonamides; Tumor Suppressor Protein p53; Ureteral Obstruction; WT1 Proteins | 2010 |
Rosuvastatin prevents myocardial necrosis in an experimental model of acute myocardial infarction.
Topics: Animals; Cholesterol, Dietary; Disease Models, Animal; Echocardiography; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Myocardial Infarction; Myocardium; Necrosis; Pyrimidines; Rats; Rats, Wistar; Rosuvastatin Calcium; Sulfonamides | 2011 |
Rosuvastatin treatment activates JAK-STAT pathway and increases efficacy of allogeneic mesenchymal stem cell transplantation in infarcted hearts.
Topics: Animals; Cell Differentiation; Cell Survival; Cell Tracking; Cells, Cultured; Disease Models, Animal; Enzyme Activation; Female; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Janus Kinase 2; Male; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Myocardial Contraction; Myocardial Infarction; Myocardium; Phosphorylation; Protein Kinase Inhibitors; Pyrimidines; Rats; Rats, Sprague-Dawley; Recovery of Function; Rosuvastatin Calcium; Signal Transduction; STAT3 Transcription Factor; Stroke Volume; Sulfonamides; Time Factors; Transplantation, Homologous; Tyrphostins; Ventricular Function, Left; Y Chromosome | 2011 |
Evaluation of LMI1195, a novel 18F-labeled cardiac neuronal PET imaging agent, in cells and animal models.
Topics: Animals; Cell Line, Tumor; Denervation; Disease Models, Animal; Fluorine Radioisotopes; Fluorobenzenes; Guanidines; Half-Life; Heart Failure; Humans; Image Processing, Computer-Assisted; Macaca fascicularis; Male; Neuroblastoma; Positron-Emission Tomography; Rabbits; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley; Sensitivity and Specificity; Tissue Distribution | 2011 |
Rosuvastatin, a new generation 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, reduces ischemia/reperfusion-induced spinal cord tissue injury in rats.
Topics: Analysis of Variance; Animals; Aorta, Abdominal; Cytoprotection; Disease Models, Animal; Fluorobenzenes; Glutathione Peroxidase; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Malondialdehyde; Motor Activity; Necrosis; Neurologic Examination; Neuroprotective Agents; Pyrimidines; Rats; Rats, Wistar; Reperfusion Injury; Rosuvastatin Calcium; Spinal Cord; Spinal Cord Injuries; Sulfonamides; Superoxide Dismutase; Time Factors | 2011 |
Enhancement of antioxidant defense mechanism by pitavastatin and rosuvastatin on obesity-induced oxidative stress in Wistar rats.
Topics: Administration, Oral; Animals; Anti-Obesity Agents; Antioxidants; Apolipoproteins B; Cholesterol, HDL; Disease Models, Animal; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lactones; Lipid Peroxides; Myocardium; Obesity; Orlistat; Oxidative Stress; Pyrimidines; Quinolines; Rats; Rats, Wistar; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Triglycerides | 2012 |
Pimavanserin, a 5-HT2A inverse agonist, reverses psychosis-like behaviors in a rodent model of Parkinson's disease.
Topics: Amphetamine; Amphetamines; Animals; Antipsychotic Agents; Behavior, Animal; Central Nervous System Stimulants; Disease Models, Animal; Dyskinesias; Fenfluramine; Fluorobenzenes; Hyperkinesis; Male; Motor Activity; Oxidopamine; Parkinson Disease; Piperidines; Psychotic Disorders; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT2A; Sensory Gating; Serotonin 5-HT2 Receptor Antagonists; Serotonin Agents; Serotonin Receptor Agonists; Substantia Nigra; Tyrosine 3-Monooxygenase; Urea | 2011 |
Effects of the selective 5-HT(7) receptor antagonist SB-269970 in animal models of psychosis and cognition.
Topics: Amphetamine; Animals; Animals, Outbred Strains; Cognition; Disease Models, Animal; Fluorobenzenes; Locomotion; Male; Phencyclidine; Phenols; Piperidines; Psychotic Disorders; Rats; Rats, Sprague-Dawley; Receptors, Serotonin; Recognition, Psychology; Serotonin Antagonists; Sulfonamides | 2012 |
Statins improve outcome in murine models of intracranial hemorrhage and traumatic brain injury: a translational approach.
Topics: Animals; Brain Damage, Chronic; Brain Injuries; Disease Models, Animal; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intracranial Hemorrhages; Male; Mice; Mice, Inbred C57BL; Neuroprotective Agents; Pyrimidines; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Translational Research, Biomedical; Treatment Outcome | 2012 |
Chronic exposure to environmental contaminant nonylphenol exacerbates adenine-induced chronic renal insufficiency: role of signaling pathways and therapeutic impact of rosuvastatin.
Topics: Adenine; Animals; Biomarkers; Blood Urea Nitrogen; Body Weight; Creatinine; Cytoprotection; Disease Models, Animal; Endothelial Cells; Environmental Pollutants; Fibrosis; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Male; Membrane Glycoproteins; Mitogen-Activated Protein Kinases; NADH, NADPH Oxidoreductases; NADPH Oxidase 1; NADPH Oxidase 2; NADPH Oxidases; Oxidative Stress; Phenols; Protein Kinase C; Proteinuria; Pyrimidines; Rats; Rats, Wistar; Renal Insufficiency, Chronic; Rosuvastatin Calcium; Signal Transduction; Sulfonamides; Time Factors | 2012 |
The effect of rosuvastatin in a murine model of influenza A infection.
Topics: Animals; Antiviral Agents; Bronchoalveolar Lavage Fluid; Cell Line; Cytokines; Disease Models, Animal; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Lung; Macrophages; Male; Mice; Mice, Inbred C57BL; Orthomyxoviridae Infections; Pneumonia; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Virus Replication | 2012 |
Attenuation of monocrotaline-induced pulmonary arterial hypertension in rats by rosuvastatin.
Topics: Animals; Antihypertensive Agents; Arterial Pressure; Disease Models, Animal; Dose-Response Relationship, Drug; Familial Primary Pulmonary Hypertension; Fluorobenzenes; Gene Expression Regulation, Enzymologic; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Male; Monocrotaline; Nitric Oxide Synthase Type III; Proliferating Cell Nuclear Antigen; Pulmonary Artery; Pyrimidines; Rats; Rats, Sprague-Dawley; rho-Associated Kinases; RNA, Messenger; Rosuvastatin Calcium; Sulfonamides; Time Factors | 2012 |
Rosuvastatin attenuates mucus secretion in a murine model of chronic asthma by inhibiting the gamma-aminobutyric acid type A receptor.
Topics: Animals; Asthma; Chronic Disease; Disease Models, Animal; Female; Fluorobenzenes; GABA-A Receptor Antagonists; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lung; Mice; Mice, Inbred BALB C; Mucus; Pyrimidines; Receptors, GABA-A; Rosuvastatin Calcium; Sulfonamides | 2012 |
GABAB-mediated rescue of altered excitatory-inhibitory balance, gamma synchrony and behavioral deficits following constitutive NMDAR-hypofunction.
Topics: Animals; Autistic Disorder; Baclofen; Disease Models, Animal; Evoked Potentials, Auditory; Exploratory Behavior; Fluorobenzenes; GABA-B Receptor Agonists; In Situ Hybridization; Intellectual Disability; Interneurons; Male; Mice; Mice, Transgenic; Parvalbumins; Phenotype; Pyramidal Cells; Receptors, N-Methyl-D-Aspartate; Risperidone; Schizophrenia; Social Behavior; Synaptic Potentials; Triazoles | 2012 |
Rosuvastatin prevents angiotensin II-induced vascular changes by inhibition of NAD(P)H oxidase and COX-1.
Topics: Angiotensin II; Animals; Atherosclerosis; Cyclooxygenase 1; Disease Models, Animal; Endothelium, Vascular; Enzyme Induction; Enzyme Inhibitors; Extracellular Matrix; Fibrosis; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mechanical Phenomena; Membrane Proteins; Mesenteric Arteries; NADPH Oxidase 4; NADPH Oxidases; Phosphorylation; Protein Processing, Post-Translational; Pyrimidines; Rats; Rats, Sprague-Dawley; Rosuvastatin Calcium; Sulfonamides; Vascular Resistance; Vasodilation | 2013 |
Assessment of the effects of NS11394 and L-838417, α2/3 subunit-selective GABA(A) [corrected] receptor-positive allosteric modulators, in tests for pain, anxiety, memory and motor function.
Topics: Allosteric Regulation; Analgesics; Animals; Anxiety; Benzimidazoles; Disease Models, Animal; Dose-Response Relationship, Drug; Fear; Fluorobenzenes; GABA-A Receptor Agonists; Male; Maze Learning; Memory Disorders; Motor Activity; Pain; Rats; Rats, Wistar; Receptors, GABA-A; Triazoles | 2012 |
Hepatic and systemic effects of rosuvastatin on an experimental model of bile duct ligation in rats.
Topics: Actins; Alanine Transaminase; Animals; Aspartate Aminotransferases; Bile Ducts; Brain; Cholestasis; Disease Models, Animal; Female; Fluorobenzenes; gamma-Glutamyltransferase; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Ligation; Liver; Malondialdehyde; NF-kappa B; Oxidative Stress; Proliferating Cell Nuclear Antigen; Protein Carbonylation; Pyrimidines; Rats; Rats, Wistar; Receptors, Tumor Necrosis Factor, Type II; Rosuvastatin Calcium; Sulfonamides; Transforming Growth Factor beta1 | 2012 |
Rosuvastatin reduced deep vein thrombosis in ApoE gene deleted mice with hyperlipidemia through non-lipid lowering effects.
Topics: Animals; Apolipoproteins E; Cell Movement; Disease Models, Animal; Fluorobenzenes; Gene Deletion; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Inflammation; Interleukin-6; Male; Mice; Mice, Knockout; Neutrophils; P-Selectin; Pyrimidines; Rosuvastatin Calcium; Serpin E2; Sulfonamides; Thrombosis; Time Factors; Vena Cava, Inferior; Venous Thrombosis | 2013 |
Pleiotropic effects of long-term monotherapy with rosuvastatin in dogs with moderate heart failure.
Topics: Animals; Disease Models, Animal; Dogs; Fluorobenzenes; Heart Failure; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Ventricular Remodeling | 2013 |
Atorvastatin and rosuvastatin do not prevent thioacetamide induced liver cirrhosis in rats.
Topics: Animals; Atorvastatin; Cell Proliferation; Cells, Cultured; Disease Models, Animal; Fluorobenzenes; Hepatic Stellate Cells; Heptanoic Acids; Hypertension, Portal; In Vitro Techniques; Incidence; Injections; Liver Cirrhosis; Liver Cirrhosis, Experimental; Male; Oxidative Stress; Pyrimidines; Pyrroles; Rats; Rats, Wistar; Rosuvastatin Calcium; Sulfonamides; Thioacetamide | 2013 |
Direct vascular and cardioprotective effects of rosuvastatin, a new HMG-CoA reductase inhibitor.
Topics: Animals; Cardiotonic Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Endothelium, Vascular; Fluorobenzenes; Hemodynamics; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mice; Mice, Inbred C57BL; Myocardial Reperfusion Injury; Nitric Oxide; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Time Factors | 2002 |
Bone marrow-derived progenitor cells modulate vascular reendothelialization and neointimal formation: effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition.
Topics: Animals; Bone Marrow Cells; Bone Marrow Transplantation; Carotid Artery Injuries; Cell Line; Disease Models, Animal; Endothelium, Vascular; Fluorobenzenes; Gene Transfer Techniques; Green Fluorescent Proteins; Hematopoietic Stem Cells; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Luminescent Proteins; Male; Mice; Mice, Inbred C57BL; Pyrimidines; Retroviridae; Rosuvastatin Calcium; Stem Cell Transplantation; Sulfonamides; Tunica Intima | 2002 |
In vivo selective inhibition of mitogen-activated protein kinase kinase 1/2 in rabbit experimental osteoarthritis is associated with a reduction in the development of structural changes.
Topics: Animals; Cartilage, Articular; Chondrocytes; Collagenases; Disease Models, Animal; Enzyme Inhibitors; Fluorobenzenes; Hindlimb; Immunohistochemistry; Longitudinal Ligaments; Male; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Matrix Metalloproteinase 1; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinase Kinases; Mitogen-Activated Protein Kinases; Osteoarthritis, Knee; Phosphorylation; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Rabbits; Synovial Membrane; Synovitis | 2003 |
Latent inhibition in 35-day-old rats is not an "adult" latent inhibition: implications for neurodevelopmental models of schizophrenia.
Topics: Aging; Amphetamine; Animals; Antipsychotic Agents; Behavior, Animal; Central Nervous System Stimulants; Clozapine; Conditioning, Classical; Disease Models, Animal; Drinking Behavior; Fluorobenzenes; Male; Models, Neurological; Movement; Neural Inhibition; Piperidines; Rats; Rats, Wistar; Schizophrenia; Time Factors | 2003 |
Serotonin 2A receptors modulate tail-skin temperature in two rodent models of estrogen deficiency-related thermoregulatory dysfunction.
Topics: Amidines; Amphetamines; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Endocrine System Diseases; Estradiol; Estrogens; Female; Fluorobenzenes; Naloxone; Ovariectomy; Piperidines; Rats; Reaction Time; Receptor, Serotonin, 5-HT2A; Serotonin Antagonists; Serotonin Receptor Agonists; Skin Temperature; Substance Withdrawal Syndrome; Telemetry; Time Factors | 2004 |
Assessment of the efficacy of different statins in murine collagen-induced arthritis.
Topics: Animals; Arthritis, Experimental; Atorvastatin; Cells, Cultured; Disease Models, Animal; Dose-Response Relationship, Drug; Fluorobenzenes; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Lymph Nodes; Male; Mice; Mice, Inbred DBA; Nuclear Proteins; Pyrimidines; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Trans-Activators; Treatment Outcome | 2004 |
Rosuvastatin exerts favourable effects on thrombosis and neointimal growth in a mouse model of endothelial injury.
Topics: Animals; Apolipoproteins E; Arteries; Cell Count; Collagen; Disease Models, Animal; Endothelium, Vascular; Female; Fibrin; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Macrophages; Male; Mice; Mice, Knockout; Muscle, Smooth, Vascular; Pyrimidines; Regeneration; Rosuvastatin Calcium; Sulfonamides; Thrombosis; Tunica Intima | 2005 |
Rosuvastatin reduces platelet activation in heart failure: role of NO bioavailability.
Topics: Animals; Cell Adhesion Molecules; Chronic Disease; Disease Models, Animal; Endothelium, Vascular; Fluorobenzenes; Heart Failure; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Microfilament Proteins; Myocardial Infarction; Nitric Oxide; Phosphoproteins; Phosphorylation; Platelet Activation; Pyrimidines; Rats; Reactive Oxygen Species; Rosuvastatin Calcium; Sulfonamides; Superoxides; Thrombosis; Vasoconstriction; Vasodilation; Ventricular Function, Left | 2005 |
Effect of rosuvastatin on hepatic production of apolipoprotein B-containing lipoproteins in an animal model of insulin resistance and metabolic dyslipidemia.
Topics: Animals; Apolipoproteins B; Cells, Cultured; Chromatography, Gel; Cricetinae; Disease Models, Animal; Dose-Response Relationship, Drug; Dyslipidemias; Electrophoresis, Polyacrylamide Gel; Fluorobenzenes; Hepatocytes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin Resistance; Liver; Male; Mesocricetus; Metabolic Syndrome; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2006 |
Cross-talk between dyslipidemia and renin-angiotensin system and the role of LOX-1 and MAPK in atherogenesis studies with the combined use of rosuvastatin and candesartan.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Atherosclerosis; Benzimidazoles; Biphenyl Compounds; Blotting, Western; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Dyslipidemias; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mice; Mice, Inbred C57BL; Mice, Knockout; Mitogen-Activated Protein Kinases; Phosphorylation; Pyrimidines; Renin-Angiotensin System; Rosuvastatin Calcium; Scavenger Receptors, Class E; Sulfonamides; Tetrazoles | 2006 |
A comparison of chlordiazepoxide, bretazenil, L838,417 and zolpidem in a validated mouse Vogel conflict test.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Behavior, Animal; Benzodiazepinones; Chlordiazepoxide; Conflict, Psychological; Disease Models, Animal; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Drinking Behavior; Drug Interactions; Electroshock; Fluorobenzenes; GABA Agents; Male; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Pyridines; Reaction Time; Reproducibility of Results; Time Factors; Triazoles; Water Deprivation; Zolpidem | 2005 |
Reduction of cerebral infarct size by the AT1-receptor blocker candesartan, the HMG-CoA reductase inhibitor rosuvastatin and their combination. An experimental study in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Brain; Cerebral Infarction; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Enzyme Activation; Enzyme Inhibitors; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Infarction, Middle Cerebral Artery; Ischemic Attack, Transient; Male; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase Type III; Pyrimidines; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Reperfusion Injury; Rosuvastatin Calcium; Sulfonamides; Tetrazoles; Treatment Outcome | 2006 |
Highly active antiretroviral therapy attenuates re-endothelialization and alters neointima formation in the rat carotid artery after balloon injury.
Topics: Animals; Antiretroviral Therapy, Highly Active; Carotid Arteries; Catheterization; Disease Models, Animal; Drug Therapy, Combination; Endothelium, Vascular; Fluorobenzenes; Humans; Muscle, Smooth, Vascular; Pyrimidines; Rats; Rats, Sprague-Dawley; Regeneration; Rosuvastatin Calcium; Sulfonamides; Tunica Intima | 2006 |
Concurrent administration of Neu2000 and lithium produces marked improvement of motor neuron survival, motor function, and mortality in a mouse model of amyotrophic lateral sclerosis.
Topics: Amyotrophic Lateral Sclerosis; Animals; Antioxidants; Apoptosis; Benzoates; Cell Survival; Disease Models, Animal; Drug Therapy, Combination; fas Receptor; Fluorobenzenes; Lithium Carbonate; meta-Aminobenzoates; Mice; Mortality; Motor Activity; Motor Neurons; Oxidative Stress; Salicylates | 2007 |
Albumin activation of NAD(P)H oxidase activity is mediated via Rac1 in proximal tubule cells.
Topics: Albumins; Albuminuria; Aminoquinolines; Animals; Blotting, Western; Cell Membrane; Cells, Cultured; Culture Media, Serum-Free; Disease Models, Animal; Endocytosis; Enzyme Activation; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Tubules, Proximal; Microscopy, Confocal; NADPH Oxidases; Opossums; Oxidative Stress; Pyrimidines; rac1 GTP-Binding Protein; Reactive Oxygen Species; Rosuvastatin Calcium; Signal Transduction; Sulfonamides | 2007 |
Cardioprotective effect of rosuvastatin in vivo is dependent on inhibition of geranylgeranyl pyrophosphate and altered RhoA membrane translocation.
Topics: Animals; Cardiovascular Agents; Cell Membrane; Cytosol; Disease Models, Animal; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocardial Infarction; Myocardial Ischemia; Myocardial Reperfusion Injury; Myocardium; Polyisoprenyl Phosphates; Protein Transport; Pyrimidines; Rats; Rats, Sprague-Dawley; rhoA GTP-Binding Protein; Rosuvastatin Calcium; Sulfonamides | 2007 |
Rosuvastatin displays anti-atherothrombotic and anti-inflammatory properties in apoE-deficient mice.
Topics: Animals; Anti-Inflammatory Agents; Aorta; Aortic Valve; Apolipoproteins E; Atherosclerosis; Cardiovascular Agents; Cholesterol; Cholesterol, Dietary; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Intercellular Adhesion Molecule-1; Macrophages; Mice; Mice, Knockout; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Thromboplastin; Time Factors; Vascular Cell Adhesion Molecule-1 | 2007 |
The protective effect of rosuvastatin on ischemic brain injury and its mechanism.
Topics: Animals; Brain Ischemia; Caspase 3; Cerebral Cortex; Disease Models, Animal; Fluorobenzenes; Male; Mice; Mice, Inbred C57BL; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2006 |
Role of Rac1 GTPase activation in atrial fibrillation.
Topics: Aged; Animals; Atrial Fibrillation; Collagen; Disease Models, Animal; Enzyme Activation; Female; Fluorobenzenes; GTP Phosphohydrolases; Heart Atria; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mice; Mice, Transgenic; NADPH Oxidases; Pyrimidines; rac1 GTP-Binding Protein; Rosuvastatin Calcium; Sulfonamides; Up-Regulation | 2007 |
Effects of rosuvastatin on glomerular capillary size-selectivity function in rats with renal mass ablation.
Topics: Animals; Capillaries; Capillary Permeability; Disease Models, Animal; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Glomerulus; Proteinuria; Pyrimidines; Rats; Rats, Sprague-Dawley; Rosuvastatin Calcium; Sulfonamides | 2007 |
Effect of rosuvastatin on insulin sensitivity in an animal model of insulin resistance: evidence for statin-induced hepatic insulin sensitization.
Topics: Adaptor Proteins, Signal Transducing; Animals; Cricetinae; Disease Models, Animal; Fluorobenzenes; Fructose; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Injections, Intravenous; Insulin; Insulin Receptor Substrate Proteins; Insulin Resistance; Liver; Male; Mesocricetus; Protein Tyrosine Phosphatase, Non-Receptor Type 1; Proto-Oncogene Proteins c-akt; Pyrimidines; Receptor, Insulin; Rosuvastatin Calcium; Signal Transduction; Sulfonamides; Triglycerides | 2008 |
Hepatoselectivity of statins: design and synthesis of 4-sulfamoyl pyrroles as HMG-CoA reductase inhibitors.
Topics: Animals; Atorvastatin; Combinatorial Chemistry Techniques; Disease Models, Animal; Fluorobenzenes; Hepatocytes; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mice; Molecular Structure; Muscle Cells; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2008 |
Intravenous rosuvastatin for acute stroke treatment: an animal study.
Topics: Acute Disease; Animals; Aorta; Disease Models, Animal; Dose-Response Relationship, Drug; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Infarction, Middle Cerebral Artery; Injections, Intravenous; Mice; Mice, Inbred Strains; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyrimidines; Recovery of Function; Reperfusion Injury; Rosuvastatin Calcium; Sulfonamides | 2008 |
Reversal of pathological pain through specific spinal GABAA receptor subtypes.
Topics: Analgesics; Animals; Brain; Capsaicin; Chronic Disease; Diazepam; Disease Models, Animal; Fluorobenzenes; Formaldehyde; Ganglia, Spinal; Hot Temperature; Inflammation; Male; Mice; Neurons; Organ Specificity; Pain; Protein Isoforms; Protein Subunits; Rats; Rats, Wistar; Receptors, GABA-A; Spinal Cord; Triazoles | 2008 |
Rosuvastatin is additive to high-dose candesartan in slowing progression of experimental mesangioproliferative glomerulosclerosis.
Topics: Animals; Benzimidazoles; Biphenyl Compounds; Disease Models, Animal; Disease Progression; Drug Therapy, Combination; Fluorobenzenes; Glomerulosclerosis, Focal Segmental; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Glomerulus; Male; Proteinuria; Pyrimidines; Rats; Rats, Wistar; Rosuvastatin Calcium; Sulfonamides; Tetrazoles | 2008 |
Attenuation of vascular/neural dysfunction in Zucker rats treated with enalapril or rosuvastatin.
Topics: Acetylcholine; Angiotensin-Converting Enzyme Inhibitors; Animals; Arterioles; Cardiovascular System; Disease Models, Animal; Enalapril; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Metabolic Syndrome; Motor Neurons; Neural Conduction; Neurons, Afferent; Nociceptors; Obesity; Peripheral Nerves; Pyrimidines; Rats; Rats, Zucker; Rosuvastatin Calcium; Sciatic Nerve; Sulfonamides; Superoxides; Tyrosine; Vasodilator Agents | 2008 |
Effects of rosuvastatin and pitavastatin on ischemia-induced myocardial stunning in dogs.
Topics: Administration, Oral; Animals; Cell Line; Cell Survival; Cholesterol; Disease Models, Animal; Dogs; Dose-Response Relationship, Drug; Energy Metabolism; Female; Fluorobenzenes; Hemodynamics; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Muscle, Skeletal; Myocardial Contraction; Myocardial Ischemia; Myocardial Stunning; Myocardium; Pyrimidines; Quinolines; Rats; Rosuvastatin Calcium; Sulfonamides; Time Factors | 2008 |
S15261, a new compound for the treatment of the insulin resistance syndrome.
Topics: Animals; Blood Glucose; Blood Pressure; Cholesterol; Disease Models, Animal; Dose-Response Relationship, Drug; Fluorenes; Fluorobenzenes; Glucose; Glucose Clamp Technique; Glucose Tolerance Test; In Vitro Techniques; Infusions, Intravenous; Insulin; Insulin Resistance; Insulin Secretion; Islets of Langerhans; Liver Glycogen; Male; Obesity; Portal Vein; Rats; Rats, Sprague-Dawley; Syndrome; Triglycerides | 1994 |
Antithrombotic activity of SR 46349, a novel, potent and selective 5-HT2 receptor antagonist.
Topics: Animals; Bleeding Time; Coronary Circulation; Depression, Chemical; Disease Models, Animal; Dogs; Fibrinolytic Agents; Fluorobenzenes; Humans; Ketanserin; Phenols; Platelet Aggregation; Platelet Aggregation Inhibitors; Rabbits; Serotonin Antagonists; Species Specificity; Thrombosis; Vasoconstriction | 1993 |
The selective 5-HT2A receptor antagonist MDL 100,907 counteracts the psychomotor stimulation ensuing manipulations with monoaminergic, glutamatergic or muscarinic neurotransmission in the mouse--implications for psychosis.
Topics: Animals; Biogenic Monoamines; Disease Models, Animal; Dizocilpine Maleate; Dopamine Uptake Inhibitors; Excitatory Amino Acid Antagonists; Fluorobenzenes; Glutamic Acid; Hallucinogens; Lysergic Acid Diethylamide; Male; Mice; Mice, Inbred Strains; Neurotransmitter Agents; Piperazines; Piperidines; Psychomotor Performance; Psychotic Disorders; Receptor, Serotonin, 5-HT2A; Receptors, Muscarinic; Receptors, Serotonin; Serotonin; Serotonin Antagonists | 1995 |
Characterization of LY344864 as a pharmacological tool to study 5-HT1F receptors: binding affinities, brain penetration and activity in the neurogenic dural inflammation model of migraine.
Topics: Animals; Brain; Carbazoles; Disease Models, Animal; Dura Mater; Fluorobenzenes; Humans; Inflammation; Male; Migraine Disorders; Protein Binding; Rats; Rats, Inbred F344; Receptor, Serotonin, 5-HT1F; Receptors, Serotonin; Recombinant Proteins; Serotonin Receptor Agonists | 1997 |
NPS 1506: a novel NMDA receptor antagonist: neuroprotective effects in a model of closed head trauma in rats.
Topics: Animals; Brain; Brain Edema; Disease Models, Animal; Fluorobenzenes; Head Injuries, Closed; Ions; Male; Neuroprotective Agents; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate | 2000 |
Verification of a canine model of transient exercise induced myocardial dysfunction: antianginal effects of flestolol, an ultra short acting beta adrenoceptor antagonist.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Animals; Blood Pressure; Disease Models, Animal; Dogs; Fluorobenzenes; Heart Rate; Myocardial Infarction; Physical Exertion; Propanolamines; Time Factors | 1990 |